We find that tumor-derived γδ T-cell immunomodulation can limit anticancer killing when γδ T cells use AIC alone but that immunomodulation can be overcome by cancer cell opsonization using anti–B7-H3 mAb therapy, which engages γδ T-cell ADCC capacity. The gene discussed is CD276; the disease is cancer.